These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26758203)

  • 1. Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.
    Sachdeva MM; Moshiri A; Leder HA; Scott AW
    J Ophthalmic Inflamm Infect; 2016 Dec; 6(1):2. PubMed ID: 26758203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
    Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
    Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
    Kanchanaranya N; Rojdamrongratana D; Piyasoonthorn P
    J Med Assoc Thai; 2015 May; 98(5):489-94. PubMed ID: 26058278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.
    Chaudhary KM; Romero JM; Ezon I; Fastenberg DM; Deramo VA
    Retina; 2013; 33(7):1407-16. PubMed ID: 23492945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
    Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
    Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Fileta JB; Scott IU; Flynn HW
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(2):143-9. PubMed ID: 24635156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.
    VanderBeek BL; Bonaffini SG; Ma L
    Ophthalmology; 2015 Nov; 122(11):2311-2315.e1. PubMed ID: 26281823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Complications of intravitreal injections--own experience].
    Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
    Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Practice Patterns for the Management of Acute Postsurgical and Postintravitreal Injection Endophthalmitis: European Vitreo-Retinal Society Endophthalmitis Study Report 1.
    Soliman MK; Gini G; Kuhn F; Iros M; Parolini B; Ozdek S; Michalewska Z; Bopp S; Adelman RA; Sallam AB;
    Ophthalmol Retina; 2019 Jun; 3(6):461-467. PubMed ID: 31043364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.
    McCannel CA
    Retina; 2011 Apr; 31(4):654-61. PubMed ID: 21330939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome.
    Dossarps D; Bron AM; Koehrer P; Aho-Glélé LS; Creuzot-Garcher C;
    Am J Ophthalmol; 2015 Jul; 160(1):17-25.e1. PubMed ID: 25892127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causative Pathogens of Endophthalmitis after Intravitreal Anti-VEGF Injection: An International Multicenter Study.
    Busch C; Iglicki M; Okada M; Gabrielle PH; Cohen S; Mariussi M; Amphornphruet A; Cebeci Z; Chaikitmongkol V; Couturier A; Fraser-Bell S; Fung AT; Iannetta D; Radecka L; Laíns I; Rodrigues TM; Lupidi M; Ozimek M; Sala-Puigdollers A; Rehak M; Loewenstein A; Zur D;
    Ophthalmologica; 2019; 241(4):211-219. PubMed ID: 30889590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
    Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC
    Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endophthalmitis.
    Durand ML
    Clin Microbiol Infect; 2013 Mar; 19(3):227-34. PubMed ID: 23438028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients.
    Matthews JL; Dubovy SR; Goldberg RA; Flynn HW
    Ophthalmology; 2014 Mar; 121(3):702-8. PubMed ID: 24439760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection.
    Roth DB; Chieh J; Spirn MJ; Green SN; Yarian DL; Chaudhry NA
    Arch Ophthalmol; 2003 Sep; 121(9):1279-82. PubMed ID: 12963610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endophthalmitis as a complication of intravitreal anti-VEGF therapy in patients with exudative age-related macular degeneration and degenerative myopia].
    Kuhicka-Trząska A; Jędrychowska-Jamhorska JJ; Kulig-Stochmal A; Morawski K; Romanowska-Dixon B
    Klin Oczna; 2015; 117(1):35-9. PubMed ID: 26349157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.